GlassScriptPhysician profile
Terry L Swezey
NPI 1114911997
$2,282.72
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $262 · 2021: $313 · 2022: $135 · 2023: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.16 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $425.90 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $393.36 | 2019-2020 | |
| Abbvie INC. | $261.16 | 2021-2022 | |
| Stryker Corporation | $171.98 | 2019 | |
| Amgen INC. | $158.59 | 2019-2020 | |
| Genentech USA, INC. | $120.90 | 2019 | |
| Novo Nordisk INC | $100.36 | 2019-2020 | |
| Lilly USA, LLC | $94.07 | 2021-2023 | Mounjaro |
| Pfizer INC. | $87.02 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $84.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $48.08 | 2019 | |
| Arbor Pharmaceuticals, INC. | $43.61 | 2019 | |
| Esperion Therapeutics, INC. | $40.38 | 2020 | |
| Glaxosmithkline, LLC. | $40.36 | 2020-2023 | Trelegy Ellipta |
| Shire North American Group INC | $39.39 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.32 | 2019 | |
| Corium, LLC | $21.59 | 2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $13.49 | 2020 | |
| Merck Sharp & Dohme LLC | $13.43 | 2019 | |
| Abbott Laboratories | $13.22 | 2022 | |
| Allergan, INC. | $12.91 | 2020 | |
| Eisai INC. | $12.53 | 2020 | |
| Dexcom, INC. | $12.51 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Swezey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.